Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12385
Title: What's new in the treatment of serious MRSA infection?
Authors: Holmes, Natasha E;Howden, Benjamin P
Affiliation: aDepartment of Infectious Diseases, Austin Centre for Infection Research, Austin Health, Heidelberg bDepartment of Microbiology and Immunology, Microbiological Diagnostic Unit, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Parkville cDepartment of Microbiology, Monash University, Clayton, Victoria, Australia.
Issue Date: 1-Dec-2014
Citation: Current Opinion in Infectious Diseases; 27(6): 471-8
Abstract: Vancomycin has been the cornerstone of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections. This review describes new MRSA-active antibiotics that have recently been introduced and highlights emerging resistance.Elevations in the vancomycin minimum inhibitory concentration within the susceptible range are associated with treatment failure and mortality in the treatment of MRSA infections. Ceftaroline and ceftobiprole are anti-MRSA cephalosporins and are noninferior to comparator agents in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and pneumonia. Tedizolid is more potent than linezolid, has improved pharmacokinetics and reduced toxicity and is active against cfr-containing S. aureus. Telavancin now has approval for treatment of hospital-acquired pneumonia, and recent phase 2 trial data showed similar cure rates in S. aureus bacteremia. Dalbavancin and oritavancin are administered once weekly and are noninferior to comparators for acute bacterial skin and skin structure infections. Resistance has emerged against many new anti-MRSA antimicrobials including ceftaroline. Combination therapy of β-lactams with vancomycin or daptomycin is increasing.Several new MRSA-active agents are now approved for use, although much of the data is derived from treatment of acute bacterial skin and skin structure infections or pneumonia. Further studies are required for more invasive infections, such as bacteremia and endocarditis.
Internal ID Number: 25211361
URI: http://ahro.austin.org.au/austinjspui/handle/1/12385
DOI: 10.1097/QCO.0000000000000101
URL: http://www.ncbi.nlm.nih.gov/pubmed/25211361
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.